Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02085408 · ClinicalTrials.gov registry record · Phase 3
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase 3 study, sponsored by ECOG-ACRIN Cancer Research Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 727
- Enrollment target
NCT02085408 is a Phase 3 study that has completed, run by ECOG-ACRIN Cancer Research Group. The registered enrollment target is 727 participants.
The verdict
NCT02085408, a Phase 3 study, has completed, sponsored by ECOG-ACRIN Cancer Research Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 727 participants
- Enrollment target
Study Summary
This randomized phase III trial studies clofarabine to see how well it works compared with daunorubicin hydrochloride and cytarabine when followed by decitabine or observation in treating older patients with newly diagnosed acute myeloid leukemia. Drugs used in chemotherapy, such as clofarabine, daunorubicin hydrochloride, cytarabine, and decitabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. It is not yet known which chemotherapy regimen is more effective in treating acute myeloid leukemia.
Interventions
- OTHER Observation
- DRUG Decitabine
- DRUG Cytarabine
- DRUG Daunorubicin
- DRUG Clofarabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 727 participants |
| Start Date | 2011-02-04 |
| Est. Completion | 2022-12-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02085408
The ClinicalTrials.gov registry entry for NCT02085408 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 727 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ECOG-ACRIN Cancer Research Group, which has 75 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Observation is the first listed.
NCT02085408 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02085408 about?
NCT02085408 is a clinical study titled "Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia". This randomized phase III trial studies clofarabine to see how well it works compared with daunorubicin hydrochloride and cytarabine when followed by decitabine or observation in treating older patients with newly diagnosed acute myeloid leukemia. Drugs used in chemotherapy, such as clofarabine, dau...
What is the current status of trial NCT02085408?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 727 participants. The study started on 2011-02-04. Estimated completion is 2022-12-21.
What interventions are being tested in trial NCT02085408?
The interventions under investigation include: Observation (OTHER), Decitabine (DRUG), Cytarabine (DRUG), Daunorubicin (DRUG), Clofarabine (DRUG).
Who is sponsoring clinical trial NCT02085408?
This trial is sponsored by ECOG-ACRIN Cancer Research Group, which has 75 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.